News for Ayala Pharmaceuticals, Inc. (AYLA)

OPENING CALL Stock futures pointed to minor losses on Monday as investors await a decision on interest rates from the Federal Reserve this week and the latest data on inflation. In Europe,...

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

SpringWorks Therapeutics receives FDA approval for its therapy but faces challenges in commercialization.

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced...

Jul 28, 2023 / 02:00PM GMTOperator Good morning, and welcome to the Ayala Pharmaceuticals annual meeting. I'll now pass the call over to Kenneth Berlin, Preside

Jun 07, 2023 / 02:00PM GMTOperator Good morning, and welcome to the Ayala Pharma post-2023 ASCO data conference call. (Operator Instructions) As a reminder, thi

Ayala completes patient enrollment for pivotal desmoid tumor study

Immunome completes enrollment for AL102 Phase 3 study

Nanomedicine is experiencing heightened demand, mainly propelled by the increasing occurrence of chronic ailments like cardiovascular, neurological,...

The demand for biopharmaceuticals is primarily driven by the increasing prevalence of chronic, infectious, and neurological diseases, coupled with the...

The triple-negative breast cancer market is witnessing significant growth and evolution due to increased awareness, technological advancements, therapeutic...

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology...

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ... | January 4, 2023

HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously working towards developing 85+ HER2 negative Breast Cancer treatment...

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest ...

GuruFocus Article or News written by insider and the topic is about:

Today's Daily Dose brings you news about encouraging data related to AC Immune's vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease; ESSA Pharma's prostate cancer trial results; GenMark's near-term catalyst; Infinity's urothelial cancer trial data; and Monopar's imaging agent to Improve surgical outcomes in bladder cancer.